On January 20, 2026, Zacks Investment Research elevated Omnicell (OMCL) to a Zacks Rank #2 (Buy) following a broad upward revision in earnings estimates. Over the past four weeks, the consensus full-year EPS forecast for fiscal 2026 rose by 14.5% from $1.10 to $1.26, driven by stronger margin projections in the automation segment. Six of eight covering analysts have raised their 12-month price targets, citing accelerating adoption of Omnicell’s AI-enabled dispensing systems in U.S. hospitals. This upgrade reflects growing confidence that autonomous medication management solutions will contribute at least 60 basis points of incremental operating margin in 2026.

Omnicell will report fourth-quarter and full-year 2025 results on Thursday, February 5, before the market opens, with a conference call at 8:30 a.m. ET (Dial-in U.S. 800-715-9871; Intl. 646-307-1963; Conference ID 4203777). During 2025, the company achieved full-year revenue of $1.21 billion, up 12% year-over-year, driven by a 18% lift in global orders for its automated pharmacy cabinets and a 25% increase in software subscription bookings. Management is expected to provide initial guidance for 2026, with analysts forecasting revenue growth of at least 10% and adjusted operating margins expanding by 100 basis points.